ChromaDex Corporation (CDXC) Dividend History

Company News

• Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report

  The chlorinated isopropane market is expected to grow at a CAGR of 4.9% from 2025 to 2035, driven by increasing demand from the pharmaceutical and agrochemical industries. The market is projected to reach $496 million by 2035.

  GlobeNewswire Inc.

  Featured Companies: ABOS
• ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

  ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.

  Zacks Investment Research

  Featured Companies: ALXO ANVS CGEN
• Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

  Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  Zacks Investment Research

  Featured Companies: DTIL
• Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates

  Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 136.36% and 15.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: KNSA
• ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

  ChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research